Ligand Pharma (LGND) PT Lowered to $185 at Roth Capital
Tweet Send to a Friend
Roth Capital analyst Scott Henry lowered the price target on Ligand Pharma (NASDAQ: LGND) to $185.00 (from $192.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
